[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCUXQSGSgwXFo_cyo8nzNWgW7kcX2b08ay28RSbgDhwE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":67,"rows":74},"Kirby Institute",[4],92,false,14,244188,10,33,[13,16,19,21,24,27,30,33],{"name":14,"count":15},"Hepatitis C",19,{"name":17,"count":18},"HIV Infections",16,{"name":20,"count":10},"HIV",{"name":22,"count":23},"Hepatitis C, Chronic",9,{"name":25,"count":26},"HIV Infection",6,{"name":28,"count":29},"Hepatitis B",5,{"name":31,"count":32},"Cardiovascular Disease",4,{"name":34,"count":35},"Pandemic Influenza",3,[37,42,47,52,57,62],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04415424","Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men","2025-06-30","4CMenB vaccine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06317051","Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","2026-07","Dapagliflozin 10mg Tab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05415267","Immunosuppression and COVID-19 Boosters","2026-12-31","diphtheria and tetanus toxoids (adsorbed) vaccine",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07509112","Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study","2027-01","12 weeks of weekly subcutaneous semaglutide",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07550595","Oritavancin for Treatment of Serious Cardiac Infections","2028-06-30","Oritavancin",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07145736","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases","2029-03-31","Moxidectin",[68,69,70,71,72,73],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[75,105,123,148,166,184,206,224,246,271,293,360,419,469,515,544,566,592,614,636,658,676,694,723,741,759,777,802,827,845,872,890,908,932,954,977,1001,1019,1037,1062,1080,1098,1126,1144,1162,1186,1204,1228,1258,1276,1294,1312,1330,1348,1366,1384,1402,1420,1438,1456,1474,1492,1510,1528,1546,1564,1589,1607,1633,1657,1681,1706,1731,1749,1775,1793,1811,1839,1857,1875,1900,1918,1943,1968,1996,2014,2039,2064,2089,2107,2132,2180,2206,2234,2252,2275,2293,2317,2335,2353,2379,2397,2419,2443,2461],{"intervention":66,"totalTrials":76,"cells":77},1,{"EARLY_PHASE1":78,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":103},{"trials":79,"activeCount":80},[],0,{"trials":82,"activeCount":80},[],{"trials":84,"activeCount":80},[],{"trials":86,"activeCount":80},[],{"trials":88,"activeCount":76,"soonestReadout":65},[89],{"nctId":63,"briefTitle":64,"status":90,"phases":91,"primaryCompletion":65,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":101},"RECRUITING",[72],"2029-06-30","2025-08-04",52000,[96,97,98,99,100],"Onchocerciasis","Ascaris Lumbricoides Infection","Trichuris Trichiura; Infection","Hookworm Infections","Scabies",[66,102],"Ivermectin",{"trials":104,"activeCount":80},[],{"intervention":102,"totalTrials":76,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":121},{"trials":108,"activeCount":80},[],{"trials":110,"activeCount":80},[],{"trials":112,"activeCount":80},[],{"trials":114,"activeCount":80},[],{"trials":116,"activeCount":76,"soonestReadout":65},[117],{"nctId":63,"briefTitle":64,"status":90,"phases":118,"primaryCompletion":65,"completion":92,"start":93,"enrollment":94,"conditions":119,"interventions":120},[72],[96,97,98,99,100],[66,102],{"trials":122,"activeCount":80},[],{"intervention":46,"totalTrials":76,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":144,"NA":146},{"trials":126,"activeCount":80},[],{"trials":128,"activeCount":80},[],{"trials":130,"activeCount":80},[],{"trials":132,"activeCount":76,"soonestReadout":45},[133],{"nctId":43,"briefTitle":44,"status":134,"phases":135,"primaryCompletion":45,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"ACTIVE_NOT_RECRUITING",[71],"2026-12","2024-12-16",300,[17,140],"Weight Gain",[46,142,143],"Pitavastatin 4 Mg Oral","Rosuvastatin and Ezetimibe",{"trials":145,"activeCount":80},[],{"trials":147,"activeCount":80},[],{"intervention":142,"totalTrials":76,"cells":149},{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":162,"NA":164},{"trials":151,"activeCount":80},[],{"trials":153,"activeCount":80},[],{"trials":155,"activeCount":80},[],{"trials":157,"activeCount":76,"soonestReadout":45},[158],{"nctId":43,"briefTitle":44,"status":134,"phases":159,"primaryCompletion":45,"completion":136,"start":137,"enrollment":138,"conditions":160,"interventions":161},[71],[17,140],[46,142,143],{"trials":163,"activeCount":80},[],{"trials":165,"activeCount":80},[],{"intervention":143,"totalTrials":76,"cells":167},{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":180,"NA":182},{"trials":169,"activeCount":80},[],{"trials":171,"activeCount":80},[],{"trials":173,"activeCount":80},[],{"trials":175,"activeCount":76,"soonestReadout":45},[176],{"nctId":43,"briefTitle":44,"status":134,"phases":177,"primaryCompletion":45,"completion":136,"start":137,"enrollment":138,"conditions":178,"interventions":179},[71],[17,140],[46,142,143],{"trials":181,"activeCount":80},[],{"trials":183,"activeCount":80},[],{"intervention":51,"totalTrials":76,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":202,"NA":204},{"trials":187,"activeCount":80},[],{"trials":189,"activeCount":80},[],{"trials":191,"activeCount":80},[],{"trials":193,"activeCount":76,"soonestReadout":50},[194],{"nctId":48,"briefTitle":49,"status":90,"phases":195,"primaryCompletion":50,"completion":50,"start":196,"enrollment":197,"conditions":198,"interventions":200},[71],"2023-07-21",320,[199],"COVID-19",[51,201],"COVID-19 vaccine",{"trials":203,"activeCount":80},[],{"trials":205,"activeCount":80},[],{"intervention":201,"totalTrials":76,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":220,"NA":222},{"trials":209,"activeCount":80},[],{"trials":211,"activeCount":80},[],{"trials":213,"activeCount":80},[],{"trials":215,"activeCount":76,"soonestReadout":50},[216],{"nctId":48,"briefTitle":49,"status":90,"phases":217,"primaryCompletion":50,"completion":50,"start":196,"enrollment":197,"conditions":218,"interventions":219},[71],[199],[51,201],{"trials":221,"activeCount":80},[],{"trials":223,"activeCount":80},[],{"intervention":41,"totalTrials":76,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":242,"NA":244},{"trials":227,"activeCount":80},[],{"trials":229,"activeCount":80},[],{"trials":231,"activeCount":80},[],{"trials":233,"activeCount":76,"soonestReadout":40},[234],{"nctId":38,"briefTitle":39,"status":134,"phases":235,"primaryCompletion":40,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":241},[71],"2025-10-30","2021-07-08",650,[240],"Neisseria Gonorrheae Infection",[41],{"trials":243,"activeCount":80},[],{"trials":245,"activeCount":80},[],{"intervention":61,"totalTrials":76,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":249,"activeCount":80},[],{"trials":251,"activeCount":80},[],{"trials":253,"activeCount":76,"soonestReadout":60},[254],{"nctId":58,"briefTitle":59,"status":255,"phases":256,"primaryCompletion":60,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":264},"NOT_YET_RECRUITING",[70],"2028-09-30","2026-07-01",20,[261,262,263],"Infective Endocarditis","Cardiac Device Infection","Gram-positive Bacterial Infections",[61,61],{"trials":266,"activeCount":80},[],{"trials":268,"activeCount":80},[],{"trials":270,"activeCount":80},[],{"intervention":56,"totalTrials":76,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":274,"activeCount":80},[],{"trials":276,"activeCount":80},[],{"trials":278,"activeCount":76,"soonestReadout":55},[279],{"nctId":53,"briefTitle":54,"status":255,"phases":280,"primaryCompletion":55,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":286},[70],"2027-03","2026-05",40,[285],"Methamphetamine Use Disorder",[56],{"trials":288,"activeCount":80},[],{"trials":290,"activeCount":80},[],{"trials":292,"activeCount":80},[],{"intervention":294,"totalTrials":32,"cells":295},"Efavirenz",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":331,"NA":358},{"trials":297,"activeCount":80},[],{"trials":299,"activeCount":80},[],{"trials":301,"activeCount":80},[],{"trials":303,"activeCount":80},[304,314,324],{"nctId":305,"briefTitle":306,"status":307,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT01516060","The Neurocognitive Sub-study of Encore1","COMPLETED",[71],"2013-03","2012-01",71,[20],[294,294],{"nctId":315,"briefTitle":316,"status":307,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":323},"NCT01451333","The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1",[71],"2012-10","2013-02","2011-09",32,[25],[294,294],{"nctId":325,"briefTitle":326,"status":307,"phases":327,"primaryCompletion":328,"completion":328,"start":320,"enrollment":283,"conditions":329,"interventions":330},"NCT01271894","The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)",[71],"2013-05",[25],[294,294],{"trials":332,"activeCount":80},[333],{"nctId":334,"briefTitle":335,"status":307,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT00192660","HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)",[72],"2006-10","2007-12","2003-02",80,[342,31],"HIV-Associated Lipodystrophy Syndrome",[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],"Lamivudine","Stavudine","Didanosine","Zidovudine","Tenofovir","Abacavir","Nevirapine","Indinavir","Saquinavir","Amprenavir","Ritonavir","Nelfinavir","Tipranavir","enfuvirtide",{"trials":359,"activeCount":80},[],{"intervention":361,"totalTrials":32,"cells":362},"Ribavirin",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":384,"NA":417},{"trials":364,"activeCount":80},[],{"trials":366,"activeCount":80},[],{"trials":368,"activeCount":80},[],{"trials":370,"activeCount":80},[371],{"nctId":372,"briefTitle":373,"status":307,"phases":374,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":380},"NCT02634008","Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G\u002FP",[71],"2021-04-30","2016-06",83,[379],"Hepatitis C, Acute",[381,382,361,383],"Paritaprevir\u002Fritonavir\u002Fombitasvir","Dasabuvir","Glecaprevir\u002Fpibrentasvir",{"trials":385,"activeCount":80},[386,397,407],{"nctId":387,"briefTitle":388,"status":307,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":395},"NCT01364090","A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2\u002F3",[72],"2015-06","2015-10","2012-06",93,[22],[396,361],"Pegylated interferon alfa 2b",{"nctId":398,"briefTitle":399,"status":307,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":405},"NCT00192569","Australian Trial in Acute Hepatitis C",[72],"2010-06","2004-07",167,[14],[406,361],"Pegylated Interferon alfa 2a",{"nctId":408,"briefTitle":409,"status":307,"phases":410,"primaryCompletion":390,"completion":390,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT01336010","Treatment of Recently Acquired Hepatitis C Virus Infection",[72],"2011-08",82,[414],"Acute Hepatitis C",[416,361],"Peginterferon alfa-2a",{"trials":418,"activeCount":80},[],{"intervention":420,"totalTrials":35,"cells":421},"raltegravir",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":467},{"trials":423,"activeCount":80},[],{"trials":425,"activeCount":80},[],{"trials":427,"activeCount":80},[],{"trials":429,"activeCount":80},[],{"trials":431,"activeCount":80},[432,444,454],{"nctId":433,"briefTitle":434,"status":307,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT00931463","A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen",[72],"2012-09","2013-08","2009-09",558,[17],[420,442,443],"2N(t)RTI","Ritonavir-boosted lopinavir",{"nctId":445,"briefTitle":446,"status":307,"phases":447,"primaryCompletion":436,"completion":437,"start":448,"enrollment":449,"conditions":450,"interventions":451},"NCT01513122","Bone and Body Comp: A Sub Study of the SECOND-LINE Study",[72],"2010-02",210,[20],[452,453,420],"Lopinavir \u002F ritonavir","2-3N(t)RTI",{"nctId":455,"briefTitle":456,"status":307,"phases":457,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":463},"NCT00772590","Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response",[72],"2010-03","2011-06","2009-03",75,[17],[464,465,466],"Raltegravir","Hyper-immune Bovine Colostrum","raltegravir and hyper-immune bovine colostrum",{"trials":468,"activeCount":80},[],{"intervention":354,"totalTrials":35,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":513},{"trials":472,"activeCount":80},[],{"trials":474,"activeCount":80},[],{"trials":476,"activeCount":80},[],{"trials":478,"activeCount":80},[],{"trials":480,"activeCount":80},[481,498,509],{"nctId":482,"briefTitle":483,"status":484,"phases":485,"primaryCompletion":486,"completion":486,"start":487,"enrollment":80,"conditions":488,"interventions":494},"NCT04183738","Inflammation and Co-Infections in D²EFT","WITHDRAWN",[72],"2022-12-19","2021-02-01",[489,490,491,492,493],"HIV-infection\u002FAids","Human Herpesvirus 4 Infections","Cytomegalovirus Infections","Human Herpesvirus 8 Infection","Human Papilloma Virus",[495,496,354,497],"NRTIs","Darunavir","Dolutegravir",{"nctId":499,"briefTitle":500,"status":501,"phases":502,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":508},"NCT03017872","Dolutegravir and Darunavir Evaluation in Adults Failing Therapy","UNKNOWN",[72],"2022-11-11","2023-10-31","2017-11-23",831,[17],[495,497,496,354],{"nctId":334,"briefTitle":335,"status":307,"phases":510,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":511,"interventions":512},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":514,"activeCount":80},[],{"intervention":348,"totalTrials":516,"cells":517},2,{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":542},{"trials":519,"activeCount":80},[],{"trials":521,"activeCount":80},[],{"trials":523,"activeCount":80},[],{"trials":525,"activeCount":80},[],{"trials":527,"activeCount":80},[528,538],{"nctId":529,"briefTitle":530,"status":307,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":537},"NCT00192595","Tenofovir in HIV\u002FHBV Coinfection",[72],"2007-01","2004-01",36,[25,536],"Hepatitis B Coinfection",[348,347],{"nctId":334,"briefTitle":335,"status":307,"phases":539,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":540,"interventions":541},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":543,"activeCount":80},[],{"intervention":347,"totalTrials":516,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":564},{"trials":547,"activeCount":80},[],{"trials":549,"activeCount":80},[],{"trials":551,"activeCount":80},[],{"trials":553,"activeCount":80},[],{"trials":555,"activeCount":80},[556,560],{"nctId":529,"briefTitle":530,"status":307,"phases":557,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":558,"interventions":559},[72],[25,536],[348,347],{"nctId":334,"briefTitle":335,"status":307,"phases":561,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":562,"interventions":563},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":565,"activeCount":80},[],{"intervention":344,"totalTrials":516,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":582,"PHASE4":584,"NA":590},{"trials":569,"activeCount":80},[],{"trials":571,"activeCount":80},[],{"trials":573,"activeCount":80},[574],{"nctId":575,"briefTitle":576,"status":307,"phases":577,"primaryCompletion":448,"completion":458,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT00985647","Pharmacokinetics of Lamivudine at Two Different Doses",[69,70],"2009-12",24,[17],[344],{"trials":583,"activeCount":80},[],{"trials":585,"activeCount":80},[586],{"nctId":334,"briefTitle":335,"status":307,"phases":587,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":588,"interventions":589},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":591,"activeCount":80},[],{"intervention":495,"totalTrials":516,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":612},{"trials":595,"activeCount":80},[],{"trials":597,"activeCount":80},[],{"trials":599,"activeCount":80},[],{"trials":601,"activeCount":80},[],{"trials":603,"activeCount":80},[604,608],{"nctId":482,"briefTitle":483,"status":484,"phases":605,"primaryCompletion":486,"completion":486,"start":487,"enrollment":80,"conditions":606,"interventions":607},[72],[489,490,491,492,493],[495,496,354,497],{"nctId":499,"briefTitle":500,"status":501,"phases":609,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":610,"interventions":611},[72],[17],[495,497,496,354],{"trials":613,"activeCount":80},[],{"intervention":496,"totalTrials":516,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":634},{"trials":617,"activeCount":80},[],{"trials":619,"activeCount":80},[],{"trials":621,"activeCount":80},[],{"trials":623,"activeCount":80},[],{"trials":625,"activeCount":80},[626,630],{"nctId":482,"briefTitle":483,"status":484,"phases":627,"primaryCompletion":486,"completion":486,"start":487,"enrollment":80,"conditions":628,"interventions":629},[72],[489,490,491,492,493],[495,496,354,497],{"nctId":499,"briefTitle":500,"status":501,"phases":631,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":632,"interventions":633},[72],[17],[495,497,496,354],{"trials":635,"activeCount":80},[],{"intervention":497,"totalTrials":516,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":656},{"trials":639,"activeCount":80},[],{"trials":641,"activeCount":80},[],{"trials":643,"activeCount":80},[],{"trials":645,"activeCount":80},[],{"trials":647,"activeCount":80},[648,652],{"nctId":482,"briefTitle":483,"status":484,"phases":649,"primaryCompletion":486,"completion":486,"start":487,"enrollment":80,"conditions":650,"interventions":651},[72],[489,490,491,492,493],[495,496,354,497],{"nctId":499,"briefTitle":500,"status":501,"phases":653,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":654,"interventions":655},[72],[17],[495,497,496,354],{"trials":657,"activeCount":80},[],{"intervention":442,"totalTrials":76,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":674},{"trials":661,"activeCount":80},[],{"trials":663,"activeCount":80},[],{"trials":665,"activeCount":80},[],{"trials":667,"activeCount":80},[],{"trials":669,"activeCount":80},[670],{"nctId":433,"briefTitle":434,"status":307,"phases":671,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":672,"interventions":673},[72],[17],[420,442,443],{"trials":675,"activeCount":80},[],{"intervention":443,"totalTrials":76,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":692},{"trials":679,"activeCount":80},[],{"trials":681,"activeCount":80},[],{"trials":683,"activeCount":80},[],{"trials":685,"activeCount":80},[],{"trials":687,"activeCount":80},[688],{"nctId":433,"briefTitle":434,"status":307,"phases":689,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":690,"interventions":691},[72],[17],[420,442,443],{"trials":693,"activeCount":80},[],{"intervention":695,"totalTrials":76,"cells":696},"Clarithromycin 500mg",{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":721},{"trials":698,"activeCount":80},[],{"trials":700,"activeCount":80},[],{"trials":702,"activeCount":80},[],{"trials":704,"activeCount":80},[],{"trials":706,"activeCount":80},[707],{"nctId":708,"briefTitle":709,"status":307,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT04132479","The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar",[72],"2018-12-31","2019-04-09","2018-01-01",313,[716],"Helicobacter Pylori Infection",[695,718,719,720,695,718,719,720],"Amoxicillin 500mg","Tinidazole 500mg","Rabeprazole 20mg",{"trials":722,"activeCount":80},[],{"intervention":718,"totalTrials":76,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":733,"NA":739},{"trials":726,"activeCount":80},[],{"trials":728,"activeCount":80},[],{"trials":730,"activeCount":80},[],{"trials":732,"activeCount":80},[],{"trials":734,"activeCount":80},[735],{"nctId":708,"briefTitle":709,"status":307,"phases":736,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":737,"interventions":738},[72],[716],[695,718,719,720,695,718,719,720],{"trials":740,"activeCount":80},[],{"intervention":719,"totalTrials":76,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":757},{"trials":744,"activeCount":80},[],{"trials":746,"activeCount":80},[],{"trials":748,"activeCount":80},[],{"trials":750,"activeCount":80},[],{"trials":752,"activeCount":80},[753],{"nctId":708,"briefTitle":709,"status":307,"phases":754,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":755,"interventions":756},[72],[716],[695,718,719,720,695,718,719,720],{"trials":758,"activeCount":80},[],{"intervention":720,"totalTrials":76,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":775},{"trials":762,"activeCount":80},[],{"trials":764,"activeCount":80},[],{"trials":766,"activeCount":80},[],{"trials":768,"activeCount":80},[],{"trials":770,"activeCount":80},[771],{"nctId":708,"briefTitle":709,"status":307,"phases":772,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":773,"interventions":774},[72],[716],[695,718,719,720,695,718,719,720],{"trials":776,"activeCount":80},[],{"intervention":778,"totalTrials":76,"cells":779},"emtricitabine\u002Ftenofovir disoproxil fumarate",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":800},{"trials":781,"activeCount":80},[],{"trials":783,"activeCount":80},[],{"trials":785,"activeCount":80},[],{"trials":787,"activeCount":80},[],{"trials":789,"activeCount":80},[790],{"nctId":791,"briefTitle":792,"status":307,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":799},"NCT02206555","PrEP Demonstration Project (PRELUDE Study)",[72],"2016-11-28","2017-12-20","2014-11-14",327,[20],[778],{"trials":801,"activeCount":80},[],{"intervention":803,"totalTrials":76,"cells":804},"Emtricitabine 200mg - Tenofovir 300mg",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":825},{"trials":806,"activeCount":80},[],{"trials":808,"activeCount":80},[],{"trials":810,"activeCount":80},[],{"trials":812,"activeCount":80},[],{"trials":814,"activeCount":80},[815],{"nctId":816,"briefTitle":817,"status":307,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":823},"NCT00192634","A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study",[72],"2008-08","2005-12",357,[17],[803,824],"Abacavir 600mg - Lamivudine 300mg",{"trials":826,"activeCount":80},[],{"intervention":824,"totalTrials":76,"cells":828},{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":843},{"trials":830,"activeCount":80},[],{"trials":832,"activeCount":80},[],{"trials":834,"activeCount":80},[],{"trials":836,"activeCount":80},[],{"trials":838,"activeCount":80},[839],{"nctId":816,"briefTitle":817,"status":307,"phases":840,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":841,"interventions":842},[72],[17],[803,824],{"trials":844,"activeCount":80},[],{"intervention":846,"totalTrials":76,"cells":847},"Pravastatin",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":870},{"trials":849,"activeCount":80},[],{"trials":851,"activeCount":80},[],{"trials":853,"activeCount":80},[],{"trials":855,"activeCount":80},[],{"trials":857,"activeCount":80},[858],{"nctId":859,"briefTitle":860,"status":307,"phases":861,"completion":862,"start":863,"enrollment":283,"conditions":864,"interventions":869},"NCT00227500","Pravastatin for Hyperlipidaemia in HIV.",[72],"2004-10","2001-07",[17,865,866,867,868,31],"Lipid Metabolism","Glucose Metabolism","Metabolic Abnormality","Lipodystrophy",[846],{"trials":871,"activeCount":80},[],{"intervention":452,"totalTrials":76,"cells":873},{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":888},{"trials":875,"activeCount":80},[],{"trials":877,"activeCount":80},[],{"trials":879,"activeCount":80},[],{"trials":881,"activeCount":80},[],{"trials":883,"activeCount":80},[884],{"nctId":445,"briefTitle":446,"status":307,"phases":885,"primaryCompletion":436,"completion":437,"start":448,"enrollment":449,"conditions":886,"interventions":887},[72],[20],[452,453,420],{"trials":889,"activeCount":80},[],{"intervention":453,"totalTrials":76,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":906},{"trials":893,"activeCount":80},[],{"trials":895,"activeCount":80},[],{"trials":897,"activeCount":80},[],{"trials":899,"activeCount":80},[],{"trials":901,"activeCount":80},[902],{"nctId":445,"briefTitle":446,"status":307,"phases":903,"primaryCompletion":436,"completion":437,"start":448,"enrollment":449,"conditions":904,"interventions":905},[72],[20],[452,453,420],{"trials":907,"activeCount":80},[],{"intervention":909,"totalTrials":76,"cells":910},"Grazoprevir\u002Felbasvir",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":930},{"trials":912,"activeCount":80},[],{"trials":914,"activeCount":80},[],{"trials":916,"activeCount":80},[],{"trials":918,"activeCount":80},[],{"trials":920,"activeCount":80},[921],{"nctId":922,"briefTitle":923,"status":924,"phases":925,"primaryCompletion":926,"completion":926,"start":927,"enrollment":321,"conditions":928,"interventions":929},"NCT02940691","Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs","TERMINATED",[72],"2018-11-01","2017-05-01",[14],[909],{"trials":931,"activeCount":80},[],{"intervention":933,"totalTrials":76,"cells":934},"DCV\u002FASV\u002FBCV",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":952},{"trials":936,"activeCount":80},[],{"trials":938,"activeCount":80},[],{"trials":940,"activeCount":80},[],{"trials":942,"activeCount":80},[],{"trials":944,"activeCount":80},[945],{"nctId":946,"briefTitle":947,"status":484,"phases":948,"primaryCompletion":376,"completion":376,"start":949,"enrollment":80,"conditions":950,"interventions":951},"NCT02292966","Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism",[72],"2015-07",[22],[933],{"trials":953,"activeCount":80},[],{"intervention":955,"totalTrials":76,"cells":956},"Maraviroc",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":965,"NA":975},{"trials":958,"activeCount":80},[],{"trials":960,"activeCount":80},[],{"trials":962,"activeCount":80},[],{"trials":964,"activeCount":80},[],{"trials":966,"activeCount":80},[967],{"nctId":968,"briefTitle":969,"status":307,"phases":970,"primaryCompletion":971,"completion":971,"start":411,"enrollment":972,"conditions":973,"interventions":974},"NCT01384682","Maraviroc Switch Collaborative Study",[72],"2015-12",399,[20],[955],{"trials":976,"activeCount":80},[],{"intervention":978,"totalTrials":76,"cells":979},"TPV\u002FPEG-IFN\u002FRBV",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":999},{"trials":981,"activeCount":80},[],{"trials":983,"activeCount":80},[],{"trials":985,"activeCount":80},[],{"trials":987,"activeCount":80},[],{"trials":989,"activeCount":80},[990],{"nctId":991,"briefTitle":992,"status":307,"phases":993,"primaryCompletion":994,"completion":995,"start":996,"enrollment":8,"conditions":997,"interventions":998},"NCT01743521","DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)",[72],"2015-11","2016-01","2013-01",[22],[978],{"trials":1000,"activeCount":80},[],{"intervention":465,"totalTrials":76,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1009,"PHASE4":1011,"NA":1017},{"trials":1004,"activeCount":80},[],{"trials":1006,"activeCount":80},[],{"trials":1008,"activeCount":80},[],{"trials":1010,"activeCount":80},[],{"trials":1012,"activeCount":80},[1013],{"nctId":455,"briefTitle":456,"status":307,"phases":1014,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":1015,"interventions":1016},[72],[17],[464,465,466],{"trials":1018,"activeCount":80},[],{"intervention":466,"totalTrials":76,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1035},{"trials":1022,"activeCount":80},[],{"trials":1024,"activeCount":80},[],{"trials":1026,"activeCount":80},[],{"trials":1028,"activeCount":80},[],{"trials":1030,"activeCount":80},[1031],{"nctId":455,"briefTitle":456,"status":307,"phases":1032,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":1033,"interventions":1034},[72],[17],[464,465,466],{"trials":1036,"activeCount":80},[],{"intervention":1038,"totalTrials":76,"cells":1039},"arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1060},{"trials":1041,"activeCount":80},[],{"trials":1043,"activeCount":80},[],{"trials":1045,"activeCount":80},[],{"trials":1047,"activeCount":80},[],{"trials":1049,"activeCount":80},[1050],{"nctId":1051,"briefTitle":1052,"status":307,"phases":1053,"primaryCompletion":971,"completion":971,"start":392,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT01637259","MARCH Renal Substudy",[72],76,[1056,20],"Proteinuria",[1038,1058,1059],"Arm 2 boosted protease inhibitors and maraviroc","Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc",{"trials":1061,"activeCount":80},[],{"intervention":1058,"totalTrials":76,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1072,"NA":1078},{"trials":1065,"activeCount":80},[],{"trials":1067,"activeCount":80},[],{"trials":1069,"activeCount":80},[],{"trials":1071,"activeCount":80},[],{"trials":1073,"activeCount":80},[1074],{"nctId":1051,"briefTitle":1052,"status":307,"phases":1075,"primaryCompletion":971,"completion":971,"start":392,"enrollment":1054,"conditions":1076,"interventions":1077},[72],[1056,20],[1038,1058,1059],{"trials":1079,"activeCount":80},[],{"intervention":1059,"totalTrials":76,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1090,"NA":1096},{"trials":1083,"activeCount":80},[],{"trials":1085,"activeCount":80},[],{"trials":1087,"activeCount":80},[],{"trials":1089,"activeCount":80},[],{"trials":1091,"activeCount":80},[1092],{"nctId":1051,"briefTitle":1052,"status":307,"phases":1093,"primaryCompletion":971,"completion":971,"start":392,"enrollment":1054,"conditions":1094,"interventions":1095},[72],[1056,20],[1038,1058,1059],{"trials":1097,"activeCount":80},[],{"intervention":1099,"totalTrials":76,"cells":1100},"Combivir",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1124},{"trials":1102,"activeCount":80},[],{"trials":1104,"activeCount":80},[],{"trials":1106,"activeCount":80},[],{"trials":1108,"activeCount":80},[],{"trials":1110,"activeCount":80},[1111],{"nctId":1112,"briefTitle":1113,"status":307,"phases":1114,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":1118,"interventions":1122},"NCT00192621","Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects",[72],"2006-12","2004-11",50,[17,1119,1120,1121,868,31],"Dyslipidemias","Glucose Metabolism Disorders","Metabolic Diseases",[1099,1123],"Kaletra",{"trials":1125,"activeCount":80},[],{"intervention":1123,"totalTrials":76,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1134,"PHASE4":1136,"NA":1142},{"trials":1129,"activeCount":80},[],{"trials":1131,"activeCount":80},[],{"trials":1133,"activeCount":80},[],{"trials":1135,"activeCount":80},[],{"trials":1137,"activeCount":80},[1138],{"nctId":1112,"briefTitle":1113,"status":307,"phases":1139,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":1140,"interventions":1141},[72],[17,1119,1120,1121,868,31],[1099,1123],{"trials":1143,"activeCount":80},[],{"intervention":396,"totalTrials":76,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1160},{"trials":1147,"activeCount":80},[],{"trials":1149,"activeCount":80},[],{"trials":1151,"activeCount":80},[],{"trials":1153,"activeCount":80},[],{"trials":1155,"activeCount":80},[1156],{"nctId":387,"briefTitle":388,"status":307,"phases":1157,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":1158,"interventions":1159},[72],[22],[396,361],{"trials":1161,"activeCount":80},[],{"intervention":1163,"totalTrials":76,"cells":1164},"Sofosbuvir 400mg [Sovaldi]",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1173,"NA":1184},{"trials":1166,"activeCount":80},[],{"trials":1168,"activeCount":80},[],{"trials":1170,"activeCount":80},[],{"trials":1172,"activeCount":80},[],{"trials":1174,"activeCount":80},[1175],{"nctId":1176,"briefTitle":1177,"status":501,"phases":1178,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1183},"NCT03855917","Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir",[72],"2026-02","2020-02-11",30,[14],[1163,383],{"trials":1185,"activeCount":80},[],{"intervention":406,"totalTrials":76,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1202},{"trials":1189,"activeCount":80},[],{"trials":1191,"activeCount":80},[],{"trials":1193,"activeCount":80},[],{"trials":1195,"activeCount":80},[],{"trials":1197,"activeCount":80},[1198],{"nctId":398,"briefTitle":399,"status":307,"phases":1199,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":1200,"interventions":1201},[72],[14],[406,361],{"trials":1203,"activeCount":80},[],{"intervention":1205,"totalTrials":76,"cells":1206},"Sofosbuvir and ribavirin",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1226},{"trials":1208,"activeCount":80},[],{"trials":1210,"activeCount":80},[],{"trials":1212,"activeCount":80},[],{"trials":1214,"activeCount":80},[],{"trials":1216,"activeCount":80},[1217],{"nctId":1218,"briefTitle":1219,"status":307,"phases":1220,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":259,"conditions":1224,"interventions":1225},"NCT02156570","DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)",[72],"2017-08","2017-12","2014-10",[14],[1205],{"trials":1227,"activeCount":80},[],{"intervention":1229,"totalTrials":76,"cells":1230},"Darunavir (DRV) 800 milligram (MG) Oral",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1256},{"trials":1232,"activeCount":80},[],{"trials":1234,"activeCount":80},[],{"trials":1236,"activeCount":80},[],{"trials":1238,"activeCount":80},[],{"trials":1240,"activeCount":80},[1241],{"nctId":1242,"briefTitle":1243,"status":307,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT03675815","Body Composition Sub-study of the D2EFT Trial",[72],"2024-01-15","2019-12-05",155,[17],[1229,1250,1251,1252,1253,1254,1255],"Ritonavir 100 MG Oral","N(t)RTIs","Dolutegravir 50 MG Oral","TDF 300 MG Oral","3TC 300 MG Oral","FTC 200 MG Oral Cap",{"trials":1257,"activeCount":80},[],{"intervention":1250,"totalTrials":76,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1274},{"trials":1261,"activeCount":80},[],{"trials":1263,"activeCount":80},[],{"trials":1265,"activeCount":80},[],{"trials":1267,"activeCount":80},[],{"trials":1269,"activeCount":80},[1270],{"nctId":1242,"briefTitle":1243,"status":307,"phases":1271,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1272,"interventions":1273},[72],[17],[1229,1250,1251,1252,1253,1254,1255],{"trials":1275,"activeCount":80},[],{"intervention":1251,"totalTrials":76,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1284,"PHASE4":1286,"NA":1292},{"trials":1279,"activeCount":80},[],{"trials":1281,"activeCount":80},[],{"trials":1283,"activeCount":80},[],{"trials":1285,"activeCount":80},[],{"trials":1287,"activeCount":80},[1288],{"nctId":1242,"briefTitle":1243,"status":307,"phases":1289,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1290,"interventions":1291},[72],[17],[1229,1250,1251,1252,1253,1254,1255],{"trials":1293,"activeCount":80},[],{"intervention":1252,"totalTrials":76,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1310},{"trials":1297,"activeCount":80},[],{"trials":1299,"activeCount":80},[],{"trials":1301,"activeCount":80},[],{"trials":1303,"activeCount":80},[],{"trials":1305,"activeCount":80},[1306],{"nctId":1242,"briefTitle":1243,"status":307,"phases":1307,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1308,"interventions":1309},[72],[17],[1229,1250,1251,1252,1253,1254,1255],{"trials":1311,"activeCount":80},[],{"intervention":1253,"totalTrials":76,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1322,"NA":1328},{"trials":1315,"activeCount":80},[],{"trials":1317,"activeCount":80},[],{"trials":1319,"activeCount":80},[],{"trials":1321,"activeCount":80},[],{"trials":1323,"activeCount":80},[1324],{"nctId":1242,"briefTitle":1243,"status":307,"phases":1325,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1326,"interventions":1327},[72],[17],[1229,1250,1251,1252,1253,1254,1255],{"trials":1329,"activeCount":80},[],{"intervention":1254,"totalTrials":76,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1346},{"trials":1333,"activeCount":80},[],{"trials":1335,"activeCount":80},[],{"trials":1337,"activeCount":80},[],{"trials":1339,"activeCount":80},[],{"trials":1341,"activeCount":80},[1342],{"nctId":1242,"briefTitle":1243,"status":307,"phases":1343,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1344,"interventions":1345},[72],[17],[1229,1250,1251,1252,1253,1254,1255],{"trials":1347,"activeCount":80},[],{"intervention":1255,"totalTrials":76,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1364},{"trials":1351,"activeCount":80},[],{"trials":1353,"activeCount":80},[],{"trials":1355,"activeCount":80},[],{"trials":1357,"activeCount":80},[],{"trials":1359,"activeCount":80},[1360],{"nctId":1242,"briefTitle":1243,"status":307,"phases":1361,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1362,"interventions":1363},[72],[17],[1229,1250,1251,1252,1253,1254,1255],{"trials":1365,"activeCount":80},[],{"intervention":416,"totalTrials":76,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1382},{"trials":1369,"activeCount":80},[],{"trials":1371,"activeCount":80},[],{"trials":1373,"activeCount":80},[],{"trials":1375,"activeCount":80},[],{"trials":1377,"activeCount":80},[1378],{"nctId":408,"briefTitle":409,"status":307,"phases":1379,"primaryCompletion":390,"completion":390,"start":411,"enrollment":412,"conditions":1380,"interventions":1381},[72],[414],[416,361],{"trials":1383,"activeCount":80},[],{"intervention":345,"totalTrials":76,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1400},{"trials":1387,"activeCount":80},[],{"trials":1389,"activeCount":80},[],{"trials":1391,"activeCount":80},[],{"trials":1393,"activeCount":80},[],{"trials":1395,"activeCount":80},[1396],{"nctId":334,"briefTitle":335,"status":307,"phases":1397,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1398,"interventions":1399},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1401,"activeCount":80},[],{"intervention":346,"totalTrials":76,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1418},{"trials":1405,"activeCount":80},[],{"trials":1407,"activeCount":80},[],{"trials":1409,"activeCount":80},[],{"trials":1411,"activeCount":80},[],{"trials":1413,"activeCount":80},[1414],{"nctId":334,"briefTitle":335,"status":307,"phases":1415,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1416,"interventions":1417},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1419,"activeCount":80},[],{"intervention":349,"totalTrials":76,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1430,"NA":1436},{"trials":1423,"activeCount":80},[],{"trials":1425,"activeCount":80},[],{"trials":1427,"activeCount":80},[],{"trials":1429,"activeCount":80},[],{"trials":1431,"activeCount":80},[1432],{"nctId":334,"briefTitle":335,"status":307,"phases":1433,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1434,"interventions":1435},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1437,"activeCount":80},[],{"intervention":350,"totalTrials":76,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1446,"PHASE4":1448,"NA":1454},{"trials":1441,"activeCount":80},[],{"trials":1443,"activeCount":80},[],{"trials":1445,"activeCount":80},[],{"trials":1447,"activeCount":80},[],{"trials":1449,"activeCount":80},[1450],{"nctId":334,"briefTitle":335,"status":307,"phases":1451,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1452,"interventions":1453},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1455,"activeCount":80},[],{"intervention":351,"totalTrials":76,"cells":1457},{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1472},{"trials":1459,"activeCount":80},[],{"trials":1461,"activeCount":80},[],{"trials":1463,"activeCount":80},[],{"trials":1465,"activeCount":80},[],{"trials":1467,"activeCount":80},[1468],{"nctId":334,"briefTitle":335,"status":307,"phases":1469,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1470,"interventions":1471},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1473,"activeCount":80},[],{"intervention":352,"totalTrials":76,"cells":1475},{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1490},{"trials":1477,"activeCount":80},[],{"trials":1479,"activeCount":80},[],{"trials":1481,"activeCount":80},[],{"trials":1483,"activeCount":80},[],{"trials":1485,"activeCount":80},[1486],{"nctId":334,"briefTitle":335,"status":307,"phases":1487,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1488,"interventions":1489},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1491,"activeCount":80},[],{"intervention":353,"totalTrials":76,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1508},{"trials":1495,"activeCount":80},[],{"trials":1497,"activeCount":80},[],{"trials":1499,"activeCount":80},[],{"trials":1501,"activeCount":80},[],{"trials":1503,"activeCount":80},[1504],{"nctId":334,"briefTitle":335,"status":307,"phases":1505,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1506,"interventions":1507},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1509,"activeCount":80},[],{"intervention":355,"totalTrials":76,"cells":1511},{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1520,"NA":1526},{"trials":1513,"activeCount":80},[],{"trials":1515,"activeCount":80},[],{"trials":1517,"activeCount":80},[],{"trials":1519,"activeCount":80},[],{"trials":1521,"activeCount":80},[1522],{"nctId":334,"briefTitle":335,"status":307,"phases":1523,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1524,"interventions":1525},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1527,"activeCount":80},[],{"intervention":356,"totalTrials":76,"cells":1529},{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1534,"PHASE3":1536,"PHASE4":1538,"NA":1544},{"trials":1531,"activeCount":80},[],{"trials":1533,"activeCount":80},[],{"trials":1535,"activeCount":80},[],{"trials":1537,"activeCount":80},[],{"trials":1539,"activeCount":80},[1540],{"nctId":334,"briefTitle":335,"status":307,"phases":1541,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1542,"interventions":1543},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1545,"activeCount":80},[],{"intervention":357,"totalTrials":76,"cells":1547},{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1562},{"trials":1549,"activeCount":80},[],{"trials":1551,"activeCount":80},[],{"trials":1553,"activeCount":80},[],{"trials":1555,"activeCount":80},[],{"trials":1557,"activeCount":80},[1558],{"nctId":334,"briefTitle":335,"status":307,"phases":1559,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":1560,"interventions":1561},[72],[342,31],[344,345,346,347,348,349,294,350,351,352,353,354,355,356,357],{"trials":1563,"activeCount":80},[],{"intervention":1565,"totalTrials":76,"cells":1566},"\"3D\" regimen",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1587},{"trials":1568,"activeCount":80},[],{"trials":1570,"activeCount":80},[],{"trials":1572,"activeCount":80},[],{"trials":1574,"activeCount":80},[],{"trials":1576,"activeCount":80},[1577],{"nctId":1578,"briefTitle":1579,"status":307,"phases":1580,"primaryCompletion":1221,"completion":1581,"start":1582,"enrollment":1583,"conditions":1584,"interventions":1585},"NCT02498015","A Phase IV Trial of Paritaprevir\u002FRitonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection",[72],"2019-03","2016-08",87,[22],[1565,1586],"\"3D\" regimen with ribavirin",{"trials":1588,"activeCount":80},[],{"intervention":1586,"totalTrials":76,"cells":1590},{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1605},{"trials":1592,"activeCount":80},[],{"trials":1594,"activeCount":80},[],{"trials":1596,"activeCount":80},[],{"trials":1598,"activeCount":80},[],{"trials":1600,"activeCount":80},[1601],{"nctId":1578,"briefTitle":1579,"status":307,"phases":1602,"primaryCompletion":1221,"completion":1581,"start":1582,"enrollment":1583,"conditions":1603,"interventions":1604},[72],[22],[1565,1586],{"trials":1606,"activeCount":80},[],{"intervention":1608,"totalTrials":76,"cells":1609},"Truvada",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1631},{"trials":1611,"activeCount":80},[],{"trials":1613,"activeCount":80},[],{"trials":1615,"activeCount":80},[],{"trials":1617,"activeCount":80},[],{"trials":1619,"activeCount":80},[1620],{"nctId":1621,"briefTitle":1622,"status":307,"phases":1623,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":1627,"conditions":1628,"interventions":1630},"NCT00335322","ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens",[72],"2011-03","2011-11","2007-02",329,[1629],"Human Immunodeficiency Virus (HIV)",[1608,1608,1608],{"trials":1632,"activeCount":80},[],{"intervention":1634,"totalTrials":76,"cells":1635},"glecaprevir",{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1642,"PHASE4":1653,"NA":1655},{"trials":1637,"activeCount":80},[],{"trials":1639,"activeCount":80},[],{"trials":1641,"activeCount":80},[],{"trials":1643,"activeCount":80},[1644],{"nctId":1645,"briefTitle":1646,"status":307,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":1650,"conditions":1651,"interventions":1652},"NCT03117569","Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir\u002FPibrentasvir in Chronic Hepatitis C Patients",[71],"2018-12-19","2017-08-21",380,[22],[1634],{"trials":1654,"activeCount":80},[],{"trials":1656,"activeCount":80},[],{"intervention":1658,"totalTrials":76,"cells":1659},"atazanavir plus raltegravir",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1677,"NA":1679},{"trials":1661,"activeCount":80},[],{"trials":1663,"activeCount":80},[],{"trials":1665,"activeCount":80},[],{"trials":1667,"activeCount":80},[1668],{"nctId":1669,"briefTitle":1670,"status":307,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":1674,"conditions":1675,"interventions":1676},"NCT00874523","Raltegravir and Atazanavir Dosing Strategy Study",[71],"2011-07","2009-07",26,[25],[1658,1658],{"trials":1678,"activeCount":80},[],{"trials":1680,"activeCount":80},[],{"intervention":1682,"totalTrials":76,"cells":1683},"TDF\u002FFTC",{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1688,"PHASE3":1690,"PHASE4":1702,"NA":1704},{"trials":1685,"activeCount":80},[],{"trials":1687,"activeCount":80},[],{"trials":1689,"activeCount":80},[],{"trials":1691,"activeCount":80},[1692],{"nctId":1693,"briefTitle":1694,"status":307,"phases":1695,"primaryCompletion":1581,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1701},"NCT02870790","Expanded PrEP Implementation in Communities in NSW",[71],"2020-10","2016-03",9733,[20,1700],"STI",[1682],{"trials":1703,"activeCount":80},[],{"trials":1705,"activeCount":80},[],{"intervention":1707,"totalTrials":76,"cells":1708},"SOF\u002FVEL for 6 weeks",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1727,"NA":1729},{"trials":1710,"activeCount":80},[],{"trials":1712,"activeCount":80},[],{"trials":1714,"activeCount":80},[],{"trials":1716,"activeCount":80},[1717],{"nctId":1718,"briefTitle":1719,"status":307,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1725},"NCT02625909","Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.",[71],"2020-03-23","2017-03-09",222,[14],[1707,1726],"SOF\u002FVEL for 12 weeks",{"trials":1728,"activeCount":80},[],{"trials":1730,"activeCount":80},[],{"intervention":1726,"totalTrials":76,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1745,"NA":1747},{"trials":1734,"activeCount":80},[],{"trials":1736,"activeCount":80},[],{"trials":1738,"activeCount":80},[],{"trials":1740,"activeCount":80},[1741],{"nctId":1718,"briefTitle":1719,"status":307,"phases":1742,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":1723,"conditions":1743,"interventions":1744},[71],[14],[1707,1726],{"trials":1746,"activeCount":80},[],{"trials":1748,"activeCount":80},[],{"intervention":1750,"totalTrials":76,"cells":1751},"Tenofovir disoproxil fumarate",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1771,"NA":1773},{"trials":1753,"activeCount":80},[],{"trials":1755,"activeCount":80},[],{"trials":1757,"activeCount":80},[],{"trials":1759,"activeCount":80},[1760],{"nctId":1761,"briefTitle":1762,"status":307,"phases":1763,"primaryCompletion":1764,"completion":1765,"start":1766,"enrollment":1767,"conditions":1768,"interventions":1770},"NCT03327155","Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial",[71],"2019-04-30","2020-07-20","2017-11-16",900,[1769],"HIV Prevention",[1750],{"trials":1772,"activeCount":80},[],{"trials":1774,"activeCount":80},[],{"intervention":381,"totalTrials":76,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1789,"NA":1791},{"trials":1778,"activeCount":80},[],{"trials":1780,"activeCount":80},[],{"trials":1782,"activeCount":80},[],{"trials":1784,"activeCount":80},[1785],{"nctId":372,"briefTitle":373,"status":307,"phases":1786,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":1787,"interventions":1788},[71],[379],[381,382,361,383],{"trials":1790,"activeCount":80},[],{"trials":1792,"activeCount":80},[],{"intervention":382,"totalTrials":76,"cells":1794},{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1807,"NA":1809},{"trials":1796,"activeCount":80},[],{"trials":1798,"activeCount":80},[],{"trials":1800,"activeCount":80},[],{"trials":1802,"activeCount":80},[1803],{"nctId":372,"briefTitle":373,"status":307,"phases":1804,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":1805,"interventions":1806},[71],[379],[381,382,361,383],{"trials":1808,"activeCount":80},[],{"trials":1810,"activeCount":80},[],{"intervention":1812,"totalTrials":76,"cells":1813},"ondansetron, ibuprofen, paracetamol",{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1820,"PHASE4":1835,"NA":1837},{"trials":1815,"activeCount":80},[],{"trials":1817,"activeCount":80},[],{"trials":1819,"activeCount":80},[],{"trials":1821,"activeCount":80},[1822],{"nctId":1823,"briefTitle":1824,"status":924,"phases":1825,"primaryCompletion":1826,"completion":1827,"start":1828,"enrollment":1829,"conditions":1830,"interventions":1831},"NCT00147355","Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy",[71],"2008-11","2008-12","2005-11",28,[17],[1812,1832,1833,1834],"Ondansetron, ibuprofen, paracetamol","metoclopramide, ibuprofen, paracetamol","Metoclopramide, codeine phosphate, ibuprofen, paracetamol",{"trials":1836,"activeCount":80},[],{"trials":1838,"activeCount":80},[],{"intervention":1833,"totalTrials":76,"cells":1840},{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1847,"PHASE4":1853,"NA":1855},{"trials":1842,"activeCount":80},[],{"trials":1844,"activeCount":80},[],{"trials":1846,"activeCount":80},[],{"trials":1848,"activeCount":80},[1849],{"nctId":1823,"briefTitle":1824,"status":924,"phases":1850,"primaryCompletion":1826,"completion":1827,"start":1828,"enrollment":1829,"conditions":1851,"interventions":1852},[71],[17],[1812,1832,1833,1834],{"trials":1854,"activeCount":80},[],{"trials":1856,"activeCount":80},[],{"intervention":1834,"totalTrials":76,"cells":1858},{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1865,"PHASE4":1871,"NA":1873},{"trials":1860,"activeCount":80},[],{"trials":1862,"activeCount":80},[],{"trials":1864,"activeCount":80},[],{"trials":1866,"activeCount":80},[1867],{"nctId":1823,"briefTitle":1824,"status":924,"phases":1868,"primaryCompletion":1826,"completion":1827,"start":1828,"enrollment":1829,"conditions":1869,"interventions":1870},[71],[17],[1812,1832,1833,1834],{"trials":1872,"activeCount":80},[],{"trials":1874,"activeCount":80},[],{"intervention":1876,"totalTrials":76,"cells":1877},"Efavirenz 600mg",{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1896,"NA":1898},{"trials":1879,"activeCount":80},[],{"trials":1881,"activeCount":80},[],{"trials":1883,"activeCount":80},[],{"trials":1885,"activeCount":80},[1886],{"nctId":1887,"briefTitle":1888,"status":307,"phases":1889,"primaryCompletion":1890,"completion":1891,"start":411,"enrollment":1892,"conditions":1893,"interventions":1894},"NCT01011413","Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.",[71],"2013-06","2014-08",636,[17],[1876,1895],"Efavirenz 400mg",{"trials":1897,"activeCount":80},[],{"trials":1899,"activeCount":80},[],{"intervention":1895,"totalTrials":76,"cells":1901},{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1908,"PHASE4":1914,"NA":1916},{"trials":1903,"activeCount":80},[],{"trials":1905,"activeCount":80},[],{"trials":1907,"activeCount":80},[],{"trials":1909,"activeCount":80},[1910],{"nctId":1887,"briefTitle":1888,"status":307,"phases":1911,"primaryCompletion":1890,"completion":1891,"start":411,"enrollment":1892,"conditions":1912,"interventions":1913},[71],[17],[1876,1895],{"trials":1915,"activeCount":80},[],{"trials":1917,"activeCount":80},[],{"intervention":1919,"totalTrials":76,"cells":1920},"Sofosbuvir (SOF)\u002FGS-5816",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1922,"activeCount":80},[],{"trials":1924,"activeCount":80},[],{"trials":1926,"activeCount":80},[1927],{"nctId":1928,"briefTitle":1929,"status":307,"phases":1930,"primaryCompletion":1931,"completion":1932,"start":1933,"enrollment":1934,"conditions":1935,"interventions":1936},"NCT02336139","A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use",[70],"2017-04-17","2018-11-28","2016-03-16",103,[14],[1919],{"trials":1938,"activeCount":80},[],{"trials":1940,"activeCount":80},[],{"trials":1942,"activeCount":80},[],{"intervention":1944,"totalTrials":76,"cells":1945},"vorapaxar",{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1962,"PHASE4":1964,"NA":1966},{"trials":1947,"activeCount":80},[],{"trials":1949,"activeCount":80},[],{"trials":1951,"activeCount":80},[1952],{"nctId":1953,"briefTitle":1954,"status":307,"phases":1955,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":1959,"conditions":1960,"interventions":1961},"NCT02394730","Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints",[69,70],"2017-11","2018-01","2015-09",65,[20],[1944],{"trials":1963,"activeCount":80},[],{"trials":1965,"activeCount":80},[],{"trials":1967,"activeCount":80},[],{"intervention":1969,"totalTrials":76,"cells":1970},"Azacitidine",{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1972,"activeCount":80},[],{"trials":1974,"activeCount":80},[],{"trials":1976,"activeCount":80},[1977],{"nctId":1978,"briefTitle":1979,"status":307,"phases":1980,"primaryCompletion":1981,"completion":1982,"start":1983,"enrollment":283,"conditions":1984,"interventions":1988},"NCT03493646","Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486",[70],"2020-09-15","2021-09-21","2018-05-18",[1985,1986,1987],"Myelodysplastic Syndromes","Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia",[1969,1989],"CC-486",{"trials":1991,"activeCount":80},[],{"trials":1993,"activeCount":80},[],{"trials":1995,"activeCount":80},[],{"intervention":1989,"totalTrials":76,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1999,"activeCount":80},[],{"trials":2001,"activeCount":80},[],{"trials":2003,"activeCount":80},[2004],{"nctId":1978,"briefTitle":1979,"status":307,"phases":2005,"primaryCompletion":1981,"completion":1982,"start":1983,"enrollment":283,"conditions":2006,"interventions":2007},[70],[1985,1986,1987],[1969,1989],{"trials":2009,"activeCount":80},[],{"trials":2011,"activeCount":80},[],{"trials":2013,"activeCount":80},[],{"intervention":2015,"totalTrials":76,"cells":2016},"pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2033,"PHASE4":2035,"NA":2037},{"trials":2018,"activeCount":80},[],{"trials":2020,"activeCount":80},[],{"trials":2022,"activeCount":80},[2023],{"nctId":2024,"briefTitle":2025,"status":924,"phases":2026,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":2031,"interventions":2032},"NCT00333424","Thai Prophylactic HIV Vaccine Phase I Study",[69,70],"2008-07","2009-02","2007-08",8,[20],[2015],{"trials":2034,"activeCount":80},[],{"trials":2036,"activeCount":80},[],{"trials":2038,"activeCount":80},[],{"intervention":2040,"totalTrials":76,"cells":2041},"Pomalidomide 2 MG Oral Capsule [Pomalyst]",{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2043,"activeCount":80},[],{"trials":2045,"activeCount":80},[],{"trials":2047,"activeCount":80},[2048],{"nctId":2049,"briefTitle":2050,"status":501,"phases":2051,"primaryCompletion":2052,"completion":2053,"start":2054,"enrollment":1674,"conditions":2055,"interventions":2057},"NCT03113942","Study of Pomalidomide in Anal Cancer Precursors",[70],"2019-03-31","2022-12-31","2017-06-14",[2056],"High Grade Squamous Intra-epithelial Lesion (HSIL)",[2040],{"trials":2059,"activeCount":80},[],{"trials":2061,"activeCount":80},[],{"trials":2063,"activeCount":80},[],{"intervention":2065,"totalTrials":76,"cells":2066},"recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2068,"activeCount":80},[],{"trials":2070,"activeCount":80},[],{"trials":2072,"activeCount":80},[2073],{"nctId":2074,"briefTitle":2075,"status":307,"phases":2076,"completion":2077,"start":2078,"enrollment":2079,"conditions":2080,"interventions":2081},"NCT00332930","ITV Extension Study",[69,70],"2003-09","2002-09",35,[20],[2065,2082],"HIV gag-pol antigens and interferon-gamma",{"trials":2084,"activeCount":80},[],{"trials":2086,"activeCount":80},[],{"trials":2088,"activeCount":80},[],{"intervention":2082,"totalTrials":76,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2092,"activeCount":80},[],{"trials":2094,"activeCount":80},[],{"trials":2096,"activeCount":80},[2097],{"nctId":2074,"briefTitle":2075,"status":307,"phases":2098,"completion":2077,"start":2078,"enrollment":2079,"conditions":2099,"interventions":2100},[69,70],[20],[2065,2082],{"trials":2102,"activeCount":80},[],{"trials":2104,"activeCount":80},[],{"trials":2106,"activeCount":80},[],{"intervention":2108,"totalTrials":76,"cells":2109},"lopinavir\u002Fritonavir",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2111,"activeCount":80},[],{"trials":2113,"activeCount":80},[2114],{"nctId":2115,"briefTitle":2116,"status":307,"phases":2117,"primaryCompletion":2118,"completion":2118,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2123},"NCT00985543","Pharmacokinetics of Lopinavir\u002FRitonavir at Three Different Doses.",[69],"2010-01","2009-10",22,[2122],"Acquired Immunodeficiency Syndrome",[2108],{"trials":2125,"activeCount":80},[],{"trials":2127,"activeCount":80},[],{"trials":2129,"activeCount":80},[],{"trials":2131,"activeCount":80},[],{"intervention":383,"totalTrials":32,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2146,"NA":2152},{"trials":2135,"activeCount":80},[],{"trials":2137,"activeCount":80},[],{"trials":2139,"activeCount":80},[],{"trials":2141,"activeCount":80},[2142],{"nctId":372,"briefTitle":373,"status":307,"phases":2143,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":2144,"interventions":2145},[71],[379],[381,382,361,383],{"trials":2147,"activeCount":80},[2148],{"nctId":1176,"briefTitle":1177,"status":501,"phases":2149,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":2150,"interventions":2151},[72],[14],[1163,383],{"trials":2153,"activeCount":80},[2154,2170],{"nctId":2155,"briefTitle":2156,"status":501,"phases":2157,"primaryCompletion":2158,"completion":2158,"start":2159,"enrollment":2160,"conditions":2161,"interventions":2167},"NCT03776760","Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination",[],"2022-08","2019-05-28",600,[14,2162,2163,2164,2165,2166],"Hepatitis","Liver Diseases","Hepatitis, Viral, Human","RNA Virus Infections","Digestive System Diseases",[2168,2169],"sofosbuvir\u002Fvelpatesvir","glecaprevir\u002Fpibrentasvir",{"nctId":2171,"briefTitle":2172,"status":307,"phases":2173,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2177,"interventions":2178},"NCT03492112","A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams",[73],"2021-11-30","2019-09-10",101,[14],[2179,383],"Sofosbuvir\u002Fvelpatasvir",{"intervention":2179,"totalTrials":516,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2200},{"trials":2183,"activeCount":80},[],{"trials":2185,"activeCount":80},[],{"trials":2187,"activeCount":80},[],{"trials":2189,"activeCount":80},[],{"trials":2191,"activeCount":80},[2192],{"nctId":2193,"briefTitle":2194,"status":307,"phases":2195,"primaryCompletion":2196,"completion":2196,"start":1223,"enrollment":2197,"conditions":2198,"interventions":2199},"NCT02064049","Surveillance and Treatment of Prisoners With Hepatitis C",[72],"2019-11",3692,[14],[2179],{"trials":2201,"activeCount":80},[2202],{"nctId":2171,"briefTitle":2172,"status":307,"phases":2203,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2204,"interventions":2205},[73],[14],[2179,383],{"intervention":2207,"totalTrials":76,"cells":2208},"Glecaprevir\u002FPibrentasvir 100 MG-40 MG Oral",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2217,"NA":2219},{"trials":2210,"activeCount":80},[],{"trials":2212,"activeCount":80},[],{"trials":2214,"activeCount":80},[],{"trials":2216,"activeCount":80},[],{"trials":2218,"activeCount":80},[],{"trials":2220,"activeCount":80},[2221],{"nctId":2222,"briefTitle":2223,"status":924,"phases":2224,"primaryCompletion":2225,"completion":2226,"start":2227,"enrollment":2228,"conditions":2229,"interventions":2232},"NCT03981211","Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs",[73],"2024-12-11","2025-09-15","2021-02-12",21,[14,2230,2231],"Liver Inflammation","Liver Cirrhoses",[2207,2233],"Sofosbuvir 400 MG + Glecaprevir\u002FPibrentasvir 100 MG-40 MG Oral",{"intervention":2233,"totalTrials":76,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2244,"NA":2246},{"trials":2237,"activeCount":80},[],{"trials":2239,"activeCount":80},[],{"trials":2241,"activeCount":80},[],{"trials":2243,"activeCount":80},[],{"trials":2245,"activeCount":80},[],{"trials":2247,"activeCount":80},[2248],{"nctId":2222,"briefTitle":2223,"status":924,"phases":2249,"primaryCompletion":2225,"completion":2226,"start":2227,"enrollment":2228,"conditions":2250,"interventions":2251},[73],[14,2230,2231],[2207,2233],{"intervention":2253,"totalTrials":76,"cells":2254},"saquinavir 500 formulation",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2256,"activeCount":80},[],{"trials":2258,"activeCount":80},[],{"trials":2260,"activeCount":80},[],{"trials":2262,"activeCount":80},[],{"trials":2264,"activeCount":80},[],{"trials":2266,"activeCount":80},[2267],{"nctId":2268,"briefTitle":2269,"status":307,"phases":2270,"primaryCompletion":2271,"completion":2271,"start":1116,"enrollment":283,"conditions":2272,"interventions":2273},"NCT00192608","A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study",[73],"2006-05",[17],[2253,2274],"cross-over arm",{"intervention":2274,"totalTrials":76,"cells":2276},{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2281,"PHASE3":2283,"PHASE4":2285,"NA":2287},{"trials":2278,"activeCount":80},[],{"trials":2280,"activeCount":80},[],{"trials":2282,"activeCount":80},[],{"trials":2284,"activeCount":80},[],{"trials":2286,"activeCount":80},[],{"trials":2288,"activeCount":80},[2289],{"nctId":2268,"briefTitle":2269,"status":307,"phases":2290,"primaryCompletion":2271,"completion":2271,"start":1116,"enrollment":283,"conditions":2291,"interventions":2292},[73],[17],[2253,2274],{"intervention":2294,"totalTrials":76,"cells":2295},"NRTI + PI",{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2297,"activeCount":80},[],{"trials":2299,"activeCount":80},[],{"trials":2301,"activeCount":80},[],{"trials":2303,"activeCount":80},[],{"trials":2305,"activeCount":80},[],{"trials":2307,"activeCount":80},[2308],{"nctId":2309,"briefTitle":2310,"status":307,"phases":2311,"primaryCompletion":971,"completion":971,"start":392,"enrollment":2312,"conditions":2313,"interventions":2314},"NCT01585753","MARCH Vascular Endothelium Substudy",[],34,[31],[2294,2315,2316],"maraviroc + PI","maraviroc + NRTI",{"intervention":2315,"totalTrials":76,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2320,"activeCount":80},[],{"trials":2322,"activeCount":80},[],{"trials":2324,"activeCount":80},[],{"trials":2326,"activeCount":80},[],{"trials":2328,"activeCount":80},[],{"trials":2330,"activeCount":80},[2331],{"nctId":2309,"briefTitle":2310,"status":307,"phases":2332,"primaryCompletion":971,"completion":971,"start":392,"enrollment":2312,"conditions":2333,"interventions":2334},[],[31],[2294,2315,2316],{"intervention":2316,"totalTrials":76,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2338,"activeCount":80},[],{"trials":2340,"activeCount":80},[],{"trials":2342,"activeCount":80},[],{"trials":2344,"activeCount":80},[],{"trials":2346,"activeCount":80},[],{"trials":2348,"activeCount":80},[2349],{"nctId":2309,"briefTitle":2310,"status":307,"phases":2350,"primaryCompletion":971,"completion":971,"start":392,"enrollment":2312,"conditions":2351,"interventions":2352},[],[31],[2294,2315,2316],{"intervention":2354,"totalTrials":76,"cells":2355},"Doxycycline",{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2362,"PHASE4":2364,"NA":2366},{"trials":2357,"activeCount":80},[],{"trials":2359,"activeCount":80},[],{"trials":2361,"activeCount":80},[],{"trials":2363,"activeCount":80},[],{"trials":2365,"activeCount":80},[],{"trials":2367,"activeCount":80},[2368],{"nctId":2369,"briefTitle":2370,"status":501,"phases":2371,"primaryCompletion":2372,"completion":2373,"start":2374,"enrollment":2375,"conditions":2376,"interventions":2378},"NCT03709459","Impact of the Daily Doxycycline Pre-exposure Prophylaxis (PrEP) on the Incidence of Syphilis, Gonorrhoea and Chlamydia",[],"2024-07-17","2024-12-17","2019-12-17",100,[2377],"STIs Prevention",[2354],{"intervention":2168,"totalTrials":76,"cells":2380},{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2385,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2382,"activeCount":80},[],{"trials":2384,"activeCount":80},[],{"trials":2386,"activeCount":80},[],{"trials":2388,"activeCount":80},[],{"trials":2390,"activeCount":80},[],{"trials":2392,"activeCount":80},[2393],{"nctId":2155,"briefTitle":2156,"status":501,"phases":2394,"primaryCompletion":2158,"completion":2158,"start":2159,"enrollment":2160,"conditions":2395,"interventions":2396},[],[14,2162,2163,2164,2165,2166],[2168,2169],{"intervention":2398,"totalTrials":76,"cells":2399},"Tenofovir + emtricitabine + raltegravir.",{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2410},{"trials":2401,"activeCount":80},[],{"trials":2403,"activeCount":80},[],{"trials":2405,"activeCount":80},[],{"trials":2407,"activeCount":80},[],{"trials":2409,"activeCount":80},[],{"trials":2411,"activeCount":80},[2412],{"nctId":2413,"briefTitle":2414,"status":307,"phases":2415,"primaryCompletion":1624,"completion":459,"start":2416,"enrollment":18,"conditions":2417,"interventions":2418},"NCT00641641","The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection",[73],"2008-03",[25],[2398],{"intervention":2420,"totalTrials":76,"cells":2421},"Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors",{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2423,"activeCount":80},[],{"trials":2425,"activeCount":80},[],{"trials":2427,"activeCount":80},[],{"trials":2429,"activeCount":80},[],{"trials":2431,"activeCount":80},[],{"trials":2433,"activeCount":80},[2434],{"nctId":2435,"briefTitle":2436,"status":307,"phases":2437,"primaryCompletion":971,"completion":971,"start":392,"enrollment":1829,"conditions":2438,"interventions":2440},"NCT01637233","MARCH Central Nervous System Substudy",[],[2439],"HIV-1 Infection",[2420,2441,2442],"Arm 2 Maraviroc and Protease Inhibitors","Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors",{"intervention":2441,"totalTrials":76,"cells":2444},{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2446,"activeCount":80},[],{"trials":2448,"activeCount":80},[],{"trials":2450,"activeCount":80},[],{"trials":2452,"activeCount":80},[],{"trials":2454,"activeCount":80},[],{"trials":2456,"activeCount":80},[2457],{"nctId":2435,"briefTitle":2436,"status":307,"phases":2458,"primaryCompletion":971,"completion":971,"start":392,"enrollment":1829,"conditions":2459,"interventions":2460},[],[2439],[2420,2441,2442],{"intervention":2442,"totalTrials":76,"cells":2462},{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2464,"activeCount":80},[],{"trials":2466,"activeCount":80},[],{"trials":2468,"activeCount":80},[],{"trials":2470,"activeCount":80},[],{"trials":2472,"activeCount":80},[],{"trials":2474,"activeCount":80},[2475],{"nctId":2435,"briefTitle":2436,"status":307,"phases":2476,"primaryCompletion":971,"completion":971,"start":392,"enrollment":1829,"conditions":2477,"interventions":2478},[],[2439],[2420,2441,2442]]